Balancing Relief and Pain: Effects of COX-2 Inhibitor Valdecoxib
Abstract
Abstract Views: 485
Valdecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, was initially acclaimed for its gastrointestinal safety and effectiveness in managing chronic inflammatory conditions and pain. It reduced gastrointestinal complications compared to other anti-inflammatory drugs, benefiting patients with complex medication regimens. The injectable form, parecoxib, was seen as promising for acute post-surgery pain management. However, clinical trials in high-risk cardiovascular patients, particularly those undergoing coronary artery bypass grafting, revealed increased risks when using higher doses of parecoxib. These findings led to the re-evaluation of valdecoxib’s safety profile and its subsequent market withdrawal due to cardiovascular concerns and reports of serious skin reactions. Despite its withdrawal, valdecoxib has garnered interest for repurposing in other conditions. Its pharmacodynamic and pharmacokinetic properties suggest potential in qualifying palmitate-induced insulin resistance in type 2 diabetes and inhibiting matrix metalloproteinases for wound healing. Its efficacy against SARS-CoV-2 highlights drug repurposing strategies for health crises like COVID-19. Valdecoxib's established success in arthritis, dysmenorrhea, and postoperative pain, along with its potential in treating glaucoma, underscores the value of repurposing existing drugs for new therapeutic purposes. In conclusion, valdecoxib exemplifies the balance between drug safety, clinical utility, and innovative repurposing. The aim of this study is to fully harness drug potential in medical science through a concerted effort made by the scientific community, regulatory bodies, and industry stakeholders to navigate the technological and regulatory hurdles.
Downloads
References
U.S. Food and Drug Administration. Drug recalls. FDA Web site. https://www.fda.gov/drugs/drug-safety-and-availability/drug-recalls. Accessed April 13, 2024.
U.S. Food and Drug Administration. Recalls, corrections and removals (devices). FDA Web site. https://www.fda.gov/medical-devices/postmarket-requirements-devices/recalls-corrections-and-removals-devices. Accessed April 13, 20024.
Chavez ML, DeKorte CJ. Valdecoxib: a review. Clin Ther. 2003;25(3):817–851. https://doi.org/10.1016/s0149-2918(03)80110-8
U.S. Food and Drug Administration. BEXTRA® valdecoxib tablets serious skin reactions. FDA Web site. https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21341lbl.pdf. Accessed April 13, 2024.
U.S. Food and Drug Administration. Postmarket drug safety information for patients and providers. FDA Web site. https://www.fda.gov/drugs/drug-safety-and-availability/postmarket-drug-safety-information-patients-and-providers. Accessed April 13, 2024.
Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Eng J Med. 2000;343(21):1520–1528. https://doi.org/10.1056/NEJM200011233432103
Drugs. Com. Valdecoxib interactions. Drugs Web site. https://www.drugs.com/drug-interactions/valdecoxib.html. Assessed April 13, 2024.
Valdecoxib. National Library of Medicine Web site. https://pubchem.ncbi.nlm.nih.gov/compound/Valdecoxib. Accessed April 13, 2024.
Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. New Eng J Med. 2005;352(11):1081–1091. https://doi.org/10.1056/NEJMoa050330
Bensen W. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: A randomized, controlled comparison with placebo and naproxen. Rheumatology. 2002;41(9):1008–1016. https://doi.org/10.1093/rheumatology/41.9.1008
Atukorala I, Hunter DJ. Valdecoxib: the rise and fall of a COX-2 inhibitor. Expert Opin Pharmacother. 2013;14(8):1077–1086. https://doi.org/10.1517/14656566.2013.783568
Obeid S, Libby P, Husni E, et al. Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial. Eur Heart J Cardiovasc Pharmacother. 2022;8(6):611–621. https://doi.org/10.1093/ehjcvp/pvac015
Sakai N, Kamimura K, Terai S. Repurposable drugs for immunotherapy and strategies to find candidate drugs. Pharmaceutics. 2023;15(9):e2190. https://doi.org/10.3390/pharmaceutics15092190
Wang X, Wang T, Chen X, et al. Efficacy and safety of oral anticoagulants in older adult patients with atrial fibrillation: pairwise and network meta-analyses. J Am Med Dir Assoc. 2023;24(8):1233–1239. https://doi.org/10.1016/j.jamda.2023.05.010
Gilligan MM, Gartung A, Sulciner ML, et al. Aspirin-triggered proresolving mediators stimulate resolution in cancer. Proc Natl Acad Sci U S A. 2019;116(13):6292–6297. https://doi.org/10.1073/pnas.1804000116
North GL. Celecoxib as adjunctive therapy for treatment of colorectal cancer. Ann Pharmacother. 2001;35(12):1638–1643. https://doi.org/10.1345/aph.10133
Gupta V, Panwar S, Pande RK, Arora R. Drug-related stevens–johnson syndrome and toxic epidermal necrolysis: a review. Ind J Critical Care Med. 2021;25(5):575–579. https://doi.org/d10.5005/jp-journals-10071-23826
Ziemer M, Wiesend CL, Vetter R, et al. Cutaneous adverse reactions to valdecoxib distinct from stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol. 2007;143(6):711–716. https://doi.org/10.1001/archderm.143.6.711
El-Malah AA, Gineinah MM, Deb PK, et al. Selective COX-2 inhibitors: road from success to controversy and the quest for repurposing. Pharmaceuticals. 2022;15(7):e827. https://doi.org/10.3390/ph15070827
Mude L, Jupudi S, Swaroop AK, Tallapaneni V, Karri VVSR. Molecular insights in repurposing selective COX-2 inhibitor celecoxib against matrix metalloproteinases in potentiating delayed wound healing: a molecular docking and MMPB/SA based analysis of molecular dynamic simulations. J Biomol Struct Dynam. 2023;42(5):2437–2448. https://doi.org/10.1080/07391102.2023.2209666
Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020;6:e14. https://doi.org/10.1038/s41421-020-0153-3
EMBL-EBI. Exploring ChEMBL data with the new ChEMBL interface. EBI Web site. https://www.ebi.ac.uk/training/events/exploring-chembl-data-new-chembl-interface-0/. Updated March 11, 2020. Accessed April 13, 2024.
Kim TJ, Lee HJ, Pyun DH, Abd El-Aty AM, Jeong JH, Jung TW. Valdecoxib improves lipid-induced skeletal muscle insulin resistance via simultaneous suppression of inflammation and endoplasmic reticulum stress. Biochem Pharmacol. 2021;188:e114557. https://doi.or/10.1016/j.bcp.2021.114557
Fenton C, Keating GM, Wagstaff AJ. Valdecoxib. Drugs. 2004;64:1231–1261. https://doi.org/10.2165/00003495-200464110-00006
Shah RR, Stonier PD. Repurposing old drugs in oncology: opportunities with clinical and regulatory challenges ahead. J Clin Pharm Ther. 2019;44(1):6–22. https://doi.org/10.1111/jcpt.12759
Gao Z, Li M, Yao F, et al. Valdecoxib protects against cell apoptosis induced by endoplasmic reticulum stress via the inhibition of PERK-ATF4-CHOP pathway in experimental glaucoma. Int J Mol Sci. 2022;32(21):e12983. https://doi.org/10.3390/ijms232112983
Pushpakom S, Iorio F, Eyers P, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2018;18:41–58. https://doi.org/10.1038/nrd.2018.168
Copyright (c) 2024 Syed Mohammad Habib, Majid Ali , Long Chiau Ming
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal
